Data on Albireo’s Odevixibat Presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
Albireo Pharma, Inc. (ALBO)
Last albireo pharma, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.albireopharma.com/investor-relations
Company Research
Source: GlobeNewswire
BOSTON, June 07, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that clinical data from a Phase 2 study of lead product candidate odevixibat (A4250), a highly potent and selective inhibitor of the ileal bile acid transporter (IBAT), in biliary atresia, Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) were presented today at the 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting in Glasgow, Scotland. “The encouraging data presented at ESPGHAN support our further study of odevixibat as a potential treatment across a range of rare cholestatic liver diseases,” said Ron Cooper, President and Chief Executive Officer of Albireo. “We look forward to advancing our IBAT inhibitors in new indications this year, and sharing topline Phase 3 data on odevixibat in PFIC by the end of 2019 or early 202
Show less
Read more
Impact Snapshot
Event Time:
ALBO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALBO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALBO alerts
High impacting Albireo Pharma, Inc. news events
Weekly update
A roundup of the hottest topics